Premium
Galectin‐3 secreted by human umbilical cord blood‐derived mesenchymal stem cells reduces amyloid‐β42 neurotoxicity in vitro
Author(s) -
Kim Ju-Yeon,
Kim Dong Hyun,
Kim Dal-Soo,
Kim Ji Hyun,
Jeong Sang Young,
Jeon Hong Bae,
Lee Eun Hui,
Yang Yoon Sun,
Oh Wonil,
Chang Jong Wook
Publication year - 2010
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2010.07.028
Subject(s) - mesenchymal stem cell , umbilical cord , neuroprotection , stem cell , neurotoxicity , cell culture , microbiology and biotechnology , cancer research , chemistry , immunology , biology , pharmacology , toxicity , genetics , organic chemistry
In this study, we found that expression and secretion of galectin‐3 (GAL‐3) were upregulated by amyloid‐β42 (Aβ42) exposure in human umbilical cord blood‐derived mesenchymal stem cell (hUCB‐MSC) without cell death. Aβ42‐exposed rat primary cortical neuronal cells co‐treated with recombinant GAL‐3 were protected from neuronal death in a dose‐dependent manner. hUCB‐MSCs were cocultured with Aβ42‐exposed rat primary neuronal cells or the neuroblastoma cell line, SH‐SY5Y in a Transwell chamber. Coculture of hUCB‐MSCs reduced cell death of Aβ42‐exposed neurons and SH‐SY5Y cells. This neuroprotective effect of hUCB‐MSCs was reduced significantly by GAL‐3 siRNA. These data suggested that hUCB‐MSC‐derived GAL‐3 is a survival factor against Aβ42 neurotoxicity.